Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Journal of Cancer Research and Clinical Oncology|May 29, 2017
An analysis of the kinetics of molecular response during the first trimester of treatment with nilotinib in newly diagnosed chronic myeloid leukemia patients in chronic phaseJuan Luis Steegmann, Dolors Colomer, Maria-Teresa Gómez-Casares, et al.
Haematologica|March 15, 2015
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomideMichel Delforge, Leonard Minuk, Jean-Claude Eisenmann, et al.
Nature Communications|January 10, 2026
Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extensionPeter Nordbeck, Ozlem Goker-Alpan, John A Bernat, et al.
Molecular Genetics and Metabolism|October 2, 2020
The impact of COVID-19 pandemic on the diagnosis and management of inborn errors of metabolism: A global perspectiveMohamed A Elmonem, Amaya Belanger-Quintana, Andrea Bordugo, et al.
Annals of Hematology|November 28, 2009
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)Carlos Santamaría, María C Chillón, Ramón García-Sanz, et al.
Plos One|March 10, 2020
Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosisJavier Lozano-Gerona, Aida Oliván-Viguera, Pablo Delgado-Wicke, et al.
Leukemia Research|February 15, 2011
Evaluation of tolerability and efficacy of imatinib mesylate in elderly patients with chronic phase CML: ELDERGLI studyFermin M Sánchez-Guijo, Soledad Durán, Josefina Galende, et al.
American Journal of Hematology|July 17, 2015
Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV studySilvia Mori, Elisabetta Vagge, Philipp le Coutre, et al.
Blood Cells, Molecules & Diseases|November 13, 2016
Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL projectPilar Giraldo, Marcio Andrade-Campos, Pilar Alfonso, et al.
Blood Cells, Molecules & Diseases|October 7, 2009
Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher diseaseCarla E M Hollak, Stephan vom Dahl, Johannes M F G Aerts, et al.
Pageof 16